Zatolmilast ( DrugBank: Zatolmilast )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
206	脆弱Ｘ症候群	3

206. 脆弱Ｘ症候群

---

臨床試験数 : 108 /  薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05358886 (ClinicalTrials.gov)	November 1, 2022	27/4/2022	A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome	Fragile X Syndrome	Drug: BPN14770/ zatolmilast;Drug: Placebo	Tetra Discovery Partners	NULL	Recruiting	18 Years	45 Years	Male	150	Phase 3	United States
2	NCT05367960 (ClinicalTrials.gov)	November 1, 2022	29/4/2022	An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome	An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome	Fragile X Syndrome	Drug: Zatolmilast/ BPN14770	Tetra Discovery Partners	NULL	Enrolling by invitation	12 Years	45 Years	Male	300	Phase 3	United States
3	NCT05163808 (ClinicalTrials.gov)	March 29, 2022	15/12/2021	A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome	Fragile X Syndrome	Drug: zatolmilast;Drug: Placebo	Tetra Discovery Partners	NULL	Recruiting	12 Years	18 Years	Male	150	Phase 2/Phase 3	United States